Literature DB >> 18770036

Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report.

Poonam Mishra1, Amanda DeVoss, Rish Pai, John Hart, Donald M Jensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18770036     DOI： 10.1007/s10620-008-0476-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

Review 1.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002).

Authors: 
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

2.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

3.  Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C.

Authors:  Julia Lörke; Andreas Erhardt; Dieter Häussinger
Journal:  Clin Gastroenterol Hepatol       Date:  2004-12       Impact factor: 11.382

4.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

5.  Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.

Authors:  E Khattab; I Chemin; I Vuillermoz; C Vieux; S Mrani; O Guillaud; C Trepo; F Zoulim
Journal:  J Clin Virol       Date:  2004-12-18       Impact factor: 3.168

6.  Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection.

Authors:  Rajesh Kannangai; Perumal Vivekanandan; Dale Netski; Shruti Mehta; Gregory D Kirk; David L Thomas; Michael Torbenson
Journal:  J Clin Virol       Date:  2007-04-23       Impact factor: 3.168

7.  A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

Authors:  G Fattovich; G Giustina; S Favarato; A Ruol
Journal:  J Hepatol       Date:  1996-01       Impact factor: 25.083

8.  Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C.

Authors:  L García-Buey; C García-Monzón; S Rodriguez; M J Borque; A García-Sánchez; R Iglesias; M DeCastro; F G Mateos; J L Vicario; A Balas
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

9.  Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C.

Authors:  L Muratori; M Lenzi; M Cataleta; F Giostra; F Cassani; G Ballardini; D Zauli; F B Bianchi
Journal:  J Hepatol       Date:  1994-08       Impact factor: 25.083
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.